Skip to content

Study of Normal Intestinal Development and Disease in Premature and Term Neonates

Study of Normal Intestinal Development and Disease in Premature and Term Neonates - a Pathway for the Study of Premature and Neonatal Intestinal Disorders Including the Roles of Nutrition, Microbes, and Cellular Physiology, and Diseases Including Necrotizing Enterocolitis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06681129
Acronym
NiiCE
Enrollment
100
Registered
2024-11-08
Start date
2025-03-17
Completion date
2034-12-31
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Development, Intestinal Disease, NEC, Necrotizing Enterocolitis

Keywords

NEC, Early Intestinal Development, Intestinal Intervention, Necrotizing Enterocolitis

Brief summary

Current research on early intestinal development is primarily performed in mouse models. While useful in many other ways, mouse models are not ideal for studying human intestine development as the timing of this process differs between the two species. Further, prior research has demonstrated that some proteins and pathways that are critical in human development have no clear role in mice. This study aims to improve the overall understanding of critical aspects of intestinal development in humans. In addition, this study will investigate the impact of intestinal diseases that are found in the early stages of life such as necrotizing enterocolitis (NEC).

Interventions

None listed

Sponsors

Boston Children's Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 2 Years
Healthy volunteers
No

Inclusion criteria

* Any neonate or infant through 2 years of age having intestinal surgery or intestinal biopsies from an esophogastroduodenoscopy (EGD) or colonoscopy.

Exclusion criteria

* Children \> 2 years of age. * Infants 0-2 years old not undergoing GI surgery or intestinal scope with biopsy procedure.

Design outcomes

Primary

MeasureTime frameDescription
Number of intestinal stem cells and mature epithelial cellsAt the time of surgery for another clinical problem.Small intestinal biopsy specimens will be collected either from discarded surgical biopsies collected for clinical reasons or from 1-2 additional small bunch biopsies (5mm) near the surgery site. The tissue will be used to 1.) generate organoids for longitudinal cell culture, 2.) analyze RNA or protein components by transcriptomic or cellular analyses or 3.) analyze histology. We do not have discrete planned outcomes because this is an investigational study and we are looking for new trends or differences.
Degree of Immune System ChangesWithin 48 hours before or after the clinically-driven surgery.We will collect a small 1 tsp amount of blood (5mL) and use this to analyze immune cell types or cytokines in the blood. These will include monocytes, T cell, B cells, and neutrophils for the cell types. Cytokines will include IL-1, IL-2, IL-3, IL-4, Il-5, IL-6, Il-8, IL10, IL-13, IL-22, IL-33, TNFa, IFNg, IFNa, MCP1, MIP1a.
Fraction of Stool Microbiome that has beneficial microbesWithin 48 hours before or after the surgery from which the biopsy is obtained.We will collect stool samples to analyze the microbiome using bulk microbial RNA sequencing.

Countries

United States

Contacts

CONTACTAmy O'Connell, MD, PhD
Amy.OConnell@childrens.harvard.edu617-919-1807
CONTACTKate Eident, BS
katherine.eident@childrens.harvard.edu617-355-2184
PRINCIPAL_INVESTIGATORAmy O'Connell, MD, PhD

Boston Children's Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026